<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02953171</url>
  </required_header>
  <id_info>
    <org_study_id>2016/1129/REK</org_study_id>
    <nct_id>NCT02953171</nct_id>
  </id_info>
  <brief_title>Probiotics in the Treatment of Irritable Bowel Syndrome</brief_title>
  <official_title>A Randomized Controlled Clinical Trial to Investigate the Efficacy of Lacto-fermented Sauerkraut and the Probiotic E. Coli Nissle 1917 in the Treatment of Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to assess the efficacy of two different probiotic products,
      lacto-fermented sauerkraut and the supplement Mutaflor, in the treatment of irritable bowel
      syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Irritable bowel syndrome (IBS) is a chronic gastrointestinal (GI) disorder that affects
      around 11% of the population globally. Several factors have been implicated in the
      pathogenesis of IBS, including psychological stress, gastrointestinal motility, and diet.
      More recently, it has become clear that the gastrointestinal microbiota may play a critical
      role in the pathophysiology of this functional GI condition.

      Gut microbiome manipulation, for example through the use of probiotic and prebiotic
      supplements, has shown some promise in the treatment of IBS. However, the research in this
      area is still in its infancy, and it remains unclear what type of intervention that is the
      preferred choice in cases of IBS. Many, if not most, probiotic supplements on the market
      today contain bacteria that are incapable of colonizing the human gut, which may partly
      explain why the health effects associated with the use of probiotics tend to be temporary,
      rather than permanent.

      Several studies have investigated how the use of probiotic supplements containing
      Bifidobacteria and Lactobacilli affect the clinical outcome of patients with IBS. However, to
      date, no studies have assessed whether fermented vegetables, a &quot;natural&quot; source of probiotic
      bacteria, are useful in the treatment of IBS. Moreover, little is known about how other types
      of probiotic bacteria, such as those belonging to the genus Escherichia, affect symptoms of
      IBS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IBS Symptom Severity Scale (IBS-SSS).</measure>
    <time_frame>Change from day 0 to day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Change from day 0 to day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal microbiome diversity</measure>
    <time_frame>Change from day 0 to day 42</time_frame>
    <description>16S rRNA gene sequences (prokaryotes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Quality of Life Scale (QOLS)</measure>
    <time_frame>Change from day 0 to day 42</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Raw sauerkraut+Probiotic capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 grams of raw, lacto-fermented sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raw sauerkraut+placebo capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 grams of raw, lacto-fermented sauerkraut + 1 placebo capsule, each day for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pasteurized sauerkraut+Probiotic capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 grams of pasteurized sauerkraut + 1 capsule of the probiotic Mutaflor, each day for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pasteurized sauerkraut+Placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>75 grams of pasteurized sauerkraut + 1 placebo capsule, each day for 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Raw, lacto-fermented sauerkraut</intervention_name>
    <description>Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.</description>
    <arm_group_label>Raw sauerkraut+Probiotic capsule</arm_group_label>
    <arm_group_label>Raw sauerkraut+placebo capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Mutaflor</intervention_name>
    <description>The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.</description>
    <arm_group_label>Raw sauerkraut+Probiotic capsule</arm_group_label>
    <arm_group_label>Pasteurized sauerkraut+Probiotic capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pasteurized sauerkraut</intervention_name>
    <description>Sauerkraut without live bacteria.</description>
    <arm_group_label>Pasteurized sauerkraut+Probiotic capsule</arm_group_label>
    <arm_group_label>Pasteurized sauerkraut+Placebo capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Capsules without probiotics</description>
    <arm_group_label>Raw sauerkraut+placebo capsule</arm_group_label>
    <arm_group_label>Pasteurized sauerkraut+Placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Rome III criteria (Criteria fulfilled for the last 6 months with symptom onset at least 3
        months prior to diagnosis):

        Recurrent abdominal pain or discomfort at least 3 days/month in the last 3 months
        associated with two or more of the following:

          1. Improvement with defecation

          2. Onset associated with a change in frequency of stool

          3. Onset associated with a change in form (appearance) of stool

        Exclusion Criteria:

          -  Psychiatric disorder

          -  Metabolic disease

          -  Chronic infection

          -  Organic gastrointestinal disorder

          -  Pregnancy

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eirik Garnås</last_name>
    <phone>45293161</phone>
    <phone_ext>0047</phone_ext>
    <email>dzs565@alumni.ku.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Volvat Medisinske Senter, Majorstuen</name>
      <address>
        <city>Oslo</city>
        <zip>0370</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peder Sandvold Olsen, MD</last_name>
      <email>studie.ibs@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Eirik Garnås</investigator_full_name>
    <investigator_title>Public Health Nutritionist</investigator_title>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>The human microbiome</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Sauerkraut</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

